Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)

Haider Mahdi; Navid Hafez; Deborah Doroshow; Davendra Sohal; Vickie Keedy; Khanh T. Do; Patricia LoRusso; Juliane Jürgensmeier; Manuel Avedissian; Jeffrey Sklar; Colin Glover; Brunella Felicetti; Emma Dean; Peter Mortimer; Geoffrey I. Shapiro; Joseph Paul Eder

Journal ArticleOPEN ACCESS

Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)

Mahdi H
Hafez N
Doroshow D
et al.

JCO Precision Oncology (2021) (5) 1432-1442

DOI: 10.1200/po.20.00439

44Citations

40Readers

Abstract

PURPOSEPoly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising therapy in cancers with homologous recombination repair deficiency. However, efficacy is limited by both intrinsic an...

Cite

CITATION STYLE

APA

Mahdi, H., Hafez, N., Doroshow, D., Sohal, D., Keedy, V., Do, K. T., … Eder, J. P. (2021). Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations). JCO Precision Oncology, (5), 1432–1442. https://doi.org/10.1200/po.20.00439

Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)

Abstract

Cite

Register to see more suggestions